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Studies of new prognostic factors form an extensive part of
the literature of oncology. Recent examples published in this
journal include studies of patients with primary cerebral
lymphoma (Blay et al., 1993), head and neck sarcomas (Eeles
et al., 1993) and testicular cancer (Steyerberg et al., 1993). In
some cases such studies may offer insight into the molecular
pathogenesis of the disease. In others they may help in
medical decision making; for example, in identifying which
patients are at sufficiently high risk of recurrence to warrant
a toxic or expensive treatment. Identification of major prog-
nostic determinants can facilitate the design of further clinical
trials, aid in inter-trial comparisons and guide the counselling
of individual patients. Unfortunately, however, the results of
different prognostic factor studies are often inconsistent or
contradictory.
Whereas widely accepted methodological principles have
evolved to guide the design, conduct, analysis and reporting
of clinical trials, no similar guidelines exist for prognostic
factor studies. McGuire (1991), Levine et al. (1991) and
Gasparini et al. (1993), discussed some general methodo-
logical problems with prognostic factor studies. Here we will
consider some of the statistical problems common to prog-
nostic factor studies as a step towards the development of
broadly acceptable principles that might guide their conduct
and reporting.
Stating objectives
There are several types of prognostic studies. Most of them
can be classified in the following three groups:
1. Early exploratory studies. Such investigations commonly
examine issues such as the association of a factor with
diagnosis and disease characteristics or the development
of reproducible assays.
2. Studies to determine whether prognostic factors provide
improved means of identifying patients at particularly
high or low risk of disease progression or death.
3. Studies to determine which subsets of patients benefit
from a given therapy.
We suggest that studies of type 1 might be called phase I
prognostic factor studies. Types 2 and 3 each include what
might be called phase II and III factor studies. The phase II
studies are exploratory and generate hypotheses from exten-
sive analysis of the data. Phase III studies are large,
confirmatory studies of prestated hypotheses, and allow for
more precise quantification of the magnitude of the effect.
The report by Gusterson et al. (1992) concluded that
breast carcinoma tumours which overexpress c-erbp-2 are less
responsive to CMF adjuvant therapy than those with a nor-
mal amount of gene product. Although this study included
specimens collected from 1,506 of the 2,504 patients in a
randomised clinical trial, it must be viewed as a phase II
Correspondence: R. Simon.
Received 18 February 1994.
study in the sense described here. There is no indication that
the focus of the study was on c-erbp-2, although the report is
restricted to this oncogene. More importantly, there is no
indication that the hypothesis that c-erb,-2 predicted
chemoresponsiveness was defined in advance or was sug-
gested by results of a previous study.
The report by Cuzick et al. (1985) on the prognostic value
of serum P2-microglobulin in myelomatosis is an example of
a phase III study. The patient population consisted of 476
patients enrolled in the Medical Research Council fourth trial
for myelomatosis. The analysis was focused on survival of all
entered patients. Serum P2-microglobulin was the only new
marker evaluated. The results indicated that serum P2-micro-
globulin was the most predictive single factor, but did not
address whether predictiveness of the new marker and stan-
dard factors was better than that of standard factors alone.
Often this will be of considerable importance. The study did
not address reproducibility of the P2-microglobulin assay and
was not based on utilisation of prognostic groups defined in
previous studies. The study did not establish the relevance of
measuring P2-microglobulin outside of clinical trials because
it did not test any therapeutic hypothesis involving P2-
microglobulin.
A principle of good research requires that hypotheses be
stated in advance. For example, a hypothesis might be that
S-phase fraction greater than 10% is prognostic for disease-
free survival over and above the influence of menopausal
status, hormonal receptor status and tumour size for node-
negative breast cancer patients who have not received adju-
vant therapy. Clearly stated hypotheses are, unfortunately,
rare in prognostic factor studies. In the terminology defined
above, there are very few phase III prognostic factor studies.
Numerous analyses with different subsets of factors, different
cut-off points for the factors, different subsets of patients and
different end points are often performed without specific
prestated hypotheses. This approach would not be objection-
able if the purpose of the analysis were viewed as screening
for interesting hypotheses to be tested in independent data
sets; if it were recognised that the results should not be
accepted without confirmation. It is unusual, however, that
authors interpret the results in that way. Unfortunately,
many authors seem unaware of the serious impact of these
'problems of multiplicity'. The probability that some
spurious associations will be found is very high. An associa-
tion giving P<0.05 in a typical exploratory analysis of a set
of progostic factors is a much weaker finding than P<0.05
for the primary question in a focused clinical trial (Tukey,
1977), and should not be interpreted in the same way.
Table I lists important components of phase III prognostic
factor studies. Several of these components have been des-
cribed previously by others (e.g. Levine et al., 1991;
McGuire, 1991; Fielding et al., 1992; Gasparini et al., 1993).
In the sections to follow, we will clarify and discuss some of
the statistical issues included in this table.
Our definition of phases describes characteristics of prog-
nostic factors studies but does not directly address the types
of studies that should be performed before a marker is
accepted for use in clinical practice outside of clinical trials.
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This is indicated in Table II in a manner simliar to that
suggested by the 1990 National Institutes of Health Consen-
sus Development Conference on the Treatment of Early
Stage Breast Cancer (Dorr, 1992). The use of prognostic
markers to select excellent-prognosis patients with node-
negative breast cancer who do not require adjuvant chemo-
therapy is currently a controversial area in which practice
guidelines would be useful. The marker assay should be
demonstrated to be reproducible and widely available with
quality control. A clinically important improvement in pre-
dictive value of the markers beyond that achievable with
recognised prognostic factors should be established. The im-
proved prediction should have easily interpreted therapeutic
implications that have been reliably established. And these
findings should be substantiated by independently confirmed
phase III marker trials.
Design issues
Study design
Prognostic factors studies can be prospective, in which newly
diagnosed patients are entered and followed up for an ade-
quate length of time to allow a comparison of outcome for
groups with different baseline values of the factors ofinterest.
Prospective studies are very time-consuming in diseases with
Table I Guidelines for phase III prognostic factor studies
1. Intra- and inter-laboratory reproducibility of assays should be
documented
2. Laboratory assays should be performed blinded to clinical
data and outcome
3. A clear inception cohort of patients should be assembled with
few (e.g. <15%) patients non-evaluable due to missing
material or data. The referral pattern and eligibility criteria
should be described so that generalisability of results can be
evaluated
4. Treatment (or absence of treatment) should be standardised
or randomised and accounted for in the analysis and interpre-
tation
5. Hypotheses to be tested should be stated in advance. The
hypotheses should include specification of end points, cut-off
values for prognostic variables, subsets ofpatients, treatment,
standard prognostic factors or classifications to be used that
are relevant to the hypotheses
6. The number of patients and number of 'events' should be
sufficiently large that statistically reliable results are
obtainable. Statistical power calculations that incorporate the
number of hypotheses to be tested and the appropriate subset
of patients (e.g. node-negative) for each hypothesis should be
described
7. Analyses should test whether new assays add predictiveness
once outcome is adjusted for the effect of standard prognostic
factors
8. The analyses should be adjusted for the number of
hypotheses to be tested
9. Analyses should be based on prespecified cut-off values for
prognostic variables or cut-offs should be avoided
10. Confidence intervals should be provided to indcate the uncer-
tainty in estimates
11. Claims of subset-specific treatment effects should be
documented by a test of the single global null hypothesis that
there is no treatment specificity involving any of the subset-
ting variables
Table II Requirements of a prognostic marker for acceptance in
clinical practice
1. Determination is reproducible and widely available with
quality control
2. Substantial predictive value beyond recognised prognostic
systems is demonstrated
3. The predictions have therapeutic implications that are readily
interpretable by the clinician and of benefit to the patient
4. Conclusions are based on independently confirmed phase III
studies
relatively good prognosis. More often, prognostic factor
studies are retrospective, in which the measurement of
interest is made on stored samples (often tumour samples).
The advantage of retrospective studies is that information
about moderate or long-term follow-up may be available
immediately, but the disadvantage is that clinical information
may be incomplete. Missing data is a common problem when
analysing retrospective data, and the necessary assumption
that the values are missing at random is difficult to assess yet
is often implausible. Clearly only prospective studies are
possible to study a new marker than cannot be measured on
stored samples.
It is widely recognised that controlled clinical trials offer
the most reliable research evidence. One reason for this is the
careful definition of inclusion and exclusion criteria. It has
been suggested that the most reliable observational studies
are those that try as far as possible to adopt the same careful
design standards as are used in clinical trials with the goal of
achieving the same answer as if an experimental study had
been performed (Gray-Donald & Kramer, 1988). Thus for
both prospective and retrospective studies inclusion and ex-
clusion criteria should be carefully defined, so thHat it is clear
to which population of patients the results can reasonably be
extrapolated. One problem sometimes encountered with
retrospective studies is that tumour specimens are unavailable
for many patients and hence the generalisability of con-
clusions to broad populations is problematic.
Clearly it is also essential that selection of patients should
not be related to outcome; this is obviously only an issue for
retrospective studies. For retrospective studies there is a risk
of bias because stored samples are likely to include a dispro-
portionate number of larger tumours (McGuire, 1991). The
characteristics of the sample thus need to be adequately
summarised.
Sample size
Most prognostic factor studies are not planned prospectively
like clinical trials with specification of hypotheses and sample
size determination to assure adequate statistical power. Frei-
man et al. (1992) showed that many clinical trials published
as 'negative' (i.e. with a non-significant treatment effect) are
really 'uniformative' because of inadequate sample size. The
issue of sample size is at least as important for prognostic
factor studies because the problems of multiple comparisons
in the selection of variables, assessment of their significance
and the comparison of models must be considered. Because
these issues complicate the determination of appropriate sam-
ple size, and because prognostic studies are generally done on
available data, sample size planning has received little atten-
tion.
Sample size calculations with survival data are complex
because several factors, including the length of follow-up and
the prevalence of the risk factor in the patient population,
need to be considered. Sample size planning for binary end
points with survival data can be performed using the method
described by Schoenfeld (1981). The required number of
events is approximately
(Zi c+ Zi P)2/(log HR)2 w(l -w)
where HR denotes the hazard ratio of the prognostic effect,
w is the prevalence of the poor risk factor and the constants
z -, and z, -p are 1.96 and 1.28 for a two-sided 5% signi-
ficance level and 90% statistical power. For example, to
detect a hazard ratio of 3 if 20% of patients are poor risk
requires observing approximately 55 events. The number of
patients required approximately equals the number of events
required divided by the expected average event rate. For the
example given, if the average event rate is only 15% over the
course of the study, this requires approximately 370 patients.
Because of the number of analyses in many prognostic factor
studies, 1% significance is often more appropriate than 5%.
In fact, significance should generally only be declared for a
phase III study if the computed P-value is less than 0.05/c,
where c is the number of comparisons made. The issue ofSTATISTICAL ASPECTS OF PROGNOSTIC FACTOR STUDIES 981
sample size is discussed more completely by Fayers and
Machin (1994).
When many variables are to be investigated, further con-
siderations are relevant and will probably override the sort of
calculation just discussed. These issues are illustrated by
considering the study of Harrell et al. (1985), who used
regression modelling with stepwise variable selection (dis-
cussed in detail later) on a large data set of patients who had
undergone cardiac catheterisation. They developed models on
a randomly selected 'training' subset of 2,113 patients, of
whom 208 had experienced cardiovascular deaths. They
developed regression models from a menu of 30 potential
prognostic factors in the training set and then examined the
degree to which prognostic discrimination deteriorated in an
independent test set of data. They found that models
developed by stepwise regression on the 30 variables vali-
dated very poorly in the 'test' set, also consisting of 2,113
patients and 208 deaths. The models determined on different
randomly selected training sets differed considerably. Other
authors have found similar instability in Cox regression
models applied to survival data (Altman & Andersen, 1989).
Harrell et al. (1985) concluded that for regression modelling
the number of events (e.g. deaths) should be at least ten
times the number of potential prognostic variables that could
be included in the model. Interactions between prognostic
factors and multiple cut-off points (both discussed below)
increase the required sample size. The ratio of 10:1 relates
number of events to number of prognostic variables studied;
it does not represent the relationship between number of
patients and number of variables finally selected. Whereas
more work is needed in this area, the ratio 10:1 is a
reasonable standard at this point for reliable prognostic
modelling. Certainly, exploratory phase II studies should be
interpreted even more circumspectly when the ratio is lower
than 10:1, especially if the sample size is also small.
So far we have considered studies which consider only
baseline data, which is the usual case. A rather different
study design is to take serial measurements of the same
marker at baseline and at several times after treatment. For
example, different authors have derived measures of short-
term changes in CA125 levels as prognostic markers in
advanced ovarian cancer, usually based on rather small data
sets. Three such summary measures have recently been com-
pared using pooled data from 11 centres (Fayers et al., 1993).
Such studies raise several new design issues on top of those
already discussed. Some of these issues were discussed by
Gail (1981). For such studies one should prospectively
specify the sequential marker change to be tested as an early
indicator of recurrence. Sequential marker assays should be
performed blinded from clinical information and should
remain blinded to clinicians until the final analysis is per-
formed. Very few sequential studies of assays are performed
in this manner. As yet we do not think that it is possible to
make general recommendations about the design and analysis
of such studies.
Use of stepwise regression
Regression models such as Cox's proportional hazards re-
gression model are often used to study the joint influence of
several prognostic factors (Cox, 1972). Sometimes the aim is
to examine the effect of a particular 'new' potentially useful
variable after allowing for the effect of existing known prog-
nostic factors - in other words, to evaluate not just whether
the new factor is prognostic, but whether it adds usefully to
existing factors, such as stage. In exploratory (phase II)
studies, however, investigators often wish to obtain par-
simonious prediction models by excluding the 'less important'
factors. In other words, they wish to reduce a set of possible
predictors to a small set of 'important' variables. It is cus-
tomary to use stepwise regression analysis for model selec-
tion. With 'forward selection' the first variable included in
the model is the one which by itself has the most statistically
significant association with patient outcome. The next
variable included is that which is most significantly
associated with patient outcome after adjustment for the
effect of the first variable, etc. Alternatively, with 'backward
elimination' all variables are entered into the model, and then
the least statistically significant variables are removed one at
a time until all the remaining variables are deemed impor-
tant. The two approaches may lead to different models.
The results of stepwise regression analysis can be difficult
to interpret and may be misleading. The main difficulty is
that the regression coefficients in the final selected model are
biased (they are on average too large) and the significance
levels associated with these coefficients are not strictly valid.
These effects result from the use of the same data to select
the model and to estimate the regression coefficients of the
variables appearing in the model. The usual procedures for
assessing the statistical significance of a regression coefficient
do not account for this selection. It is customary, however, to
ignore these issues when interpreting P-values from stepwise
regression, with the consequent risk of false claims of statis-
tical significance.
Another difficulty is that the order of entry of variables is
often interpreted as order of 'importance' of the variables. A
variable with two levels, low and high, may effecively distin-
guish low- from high-risk patients. But if the high level is of
low prevalance, the variable will be less significantly
associated with outcome, and therefore judged to be less
important than another variable whose levels are more
balanced but which is less prognostic. Another problem with
this definition of importance is that with forward selection
the variable selected first will have great influence on what
variable is considered second most important. Thus, a
variable that is highly correlated with the variable selected
first may appear not to be at all important. Further,
although it is customary to include variables significant at the
5% level, this is an arbitrary criterion, having no direct
relation to clinical importance. Also, the number of variables
in the model will tend to increase as the sample size increases
(Harrell et al., 1985).
A third problem with stepwise regression is that the
variables selected may be highly unstable. That is, minor
changes in the data may result in the selection of a different
set of predictors. Unfortunately, the labelling of certain
variables as important (and, by implication, others as not
important) misrepresents the fact that models based on very
different sets of factors may predict almost equally well
(Hauck & Miike, 1991). If stepwise regression analysis is
used, it is desirable for the stability of the model to be
evaluated, for example by using new methods such as boot-
strap resampling (Altman & Anderson, 1989). With this
approach multiple data sets with a structure similar to the
original data are simulated, and models are developed on
each simulated data set.
In many cases it is desirable to avoid the problems of
stepwise regression. If it is important to determine whether a
new factor adds prognostic information to that already con-
tained in the more established factors, this should not be
addressed by stepwise regression. Rather, a regression model
should be fitted containing only the standard factors and
then a model fitted containing both the standard factors and
the new factor(s). The difference in the fit to the data of the
two models provides a measure of statistical significance of
whether the new factor(s) contain additional prognostic in-
formation. If there are multiple factors, then this approach
provides a way of accounting for the number of factors in
the calculation of statistical significance because one should
first test the single overall hypothesis that none of the factors
adds important information. Although such tests of the
global null hypothesis are used infrequently, they are impor-
tant for phase III studies that examine multiple factors.
Another difficulty with multiple regression methods, whether
or not stepwise procedures are used, is how to deal with
missing data. As noted in the section on study design, miss-
ing data can be a serious problem, especially in retrospective
studies, and the percentage of subjects with full data can be982 R. SIMON & D.G. ALTMAN
quite low. Various strategies for dealing with missing data
are considered by George (1988).
Continuous prognostic factors
Although we often expect risk to increase or decrease syste-
matically as the level of a marker increases, many researchers
prefer to construct high- and low-risk groups. Patients are
often divided into two equal groups by splitting at the
median value, but there is no a priori reason to suppose that
half of the patients are at higher risk (Hilsenbeck et al.,
1992). Some investigators are interested in determining what
cut-off point for a new marker best distinguishes risk groups.
The cut-off point problem is sometimes addressed by compu-
ting a statistical significance level for all possible cut-off
points and then selecting the cut-off point with the smallest
significance level. This approach is problematic because the
selected cut-off point is often used in computing P-values for
that prognostic factor, for displaying survival curves compar-
ing patients above and below the cut-off point and for regres-
sion analyses involving that factor. The P-values, survival
curves and regression coefficients resulting from these
analyses are biased by preselection of the cut-off point using
the same data (Altman, 1992; Hilsenbeck et al., 1992). Alt-
man et al. (1994) showed that for this procedure the false-
positive error rate when the marker is not prognostic is close
to 40% rather than the nominal 5%. This was also illustrated
by Courdi et al. (1988) using data for hormonal receptors
and labelling index for patients with primary breast cancer.
Altman (1992) showed how the statistical significance of the
log-rank test comparing survival curves should be adjusted
for the use of 'data-derived' optimal cut-off point.
A cut-off point reported from other studies or a value
representing the median (or some other centile) can be used
without introducing bias. Another unbiased approach is to
define the cut-off point based on the distribution of marker
level among patients without use of clinical outcome data.
For example, if most patients have a marker level close to
zero and the rest have a level with mean 10 and standard
deviation 2, then a cut-off point of 5 for positivity might be
reasonable regardless of what the median is.
While it may be convenient to group the patients into risk
groups, categorising a variable discards information, espec-
ially if only two groups are created. The use of several
categories is preferable as it retains more information and
allows some idea of how the risk varies across the range of
values of the marker. An alternative approach is to evaluate
prognostic importance without introducing any cut-off points
at all. Representing the marker as a continuous variable has
the considerable advantage of retaining all the information,
but many researchers are unhappy to assume that the rela-
tion with outcome is linear, i.e. that the risk (measured by
the log hazard ratio) increases linearly as the variable
increases. The assumption of linearity can be tested, but
unfortunately the conventional use of an additional quadratic
term in the model is not always satisfactory. Newer methods
of regression splines (Harrell et al., 1985; Durrleman &
Simon, 1989), generalised additive models (Hastie et al.,
1992) or fractional polynomial models (Royston & Altman,
1994) can be used effectively for this purpose. These
approaches give a reliable assessment of the nature of the
relation between values of the marker and risk, and so
provide valuable information about how patient outcome
varies with level of the marker. Cut-off points, if needed, can
then be defined. The relationship between risk and marker
level is represented by the modelled regression function and
its confidence bands, rather than the' biased display of sur-
vival curves based on data-derived cut-off points.
Evaluating the predictiveness of a model
The fact that a marker is statistically significantly associated
with outcome does not necessarily mean that it is important.
Importance depends on the degree to which the marker
influences patient outcome. Statistical significance is merely
an indicator of whether the hypothesis of no prognostic effect
can be ruled out. For multiple linear regression, the multiple
correlation coefficient R2 measures the proportion of vari-
ability explained by the model and is a reflection of the
strength of the prognostic model. Similar measures have been
developed for survival models (Korn & Simon, 1990).
Graphical display of survival curves for different prognos-
tic groups is a popular and more direct way of expressing the
discriminatory power of a prognostic model. Usually, how-
ever, these graphs overestimate the model value because the
same data used for selecting variables and estimating regres-
sion coefficients are then applied to measure prognostic
effect. Even a sufficiently large number of random variables
having no true association with patient outcome will provide
an excellent fit to a limited data set. The model will have no
predictive power for independent data, however. Overfitting
data with complex models and then claiming good discrim-
inatory power based on survival curves on that same set of
data is a common problem in the medical lit6rature. A fair
evaluation of discriminatory power of a predictive model
requires either independent data or sample splitting. With
sample splitting one portion of the data is used for model
development and another for evaluating discriminatory
power for the model developed in the first portion (Harrell et
al., 1985).
One commonly sees Kaplan-Meier curves claiming to
show the difference in survival attributable to a particular
variable. These plots correspond to univariate (log-rank)
tests, however, and so do not indicate the effect of the
variable of interest after adjustment for the other variables
that may influence survival. For example, if women have a
different age distribution than men and if age is prognostic
for survival, then unadjusted survival curves will reflect an
apparent prognostic effect of sex. It is preferable to produce
plots based on prognostic categories defined by a prognostic
index (see below), or to use a method to adjust the Kaplan-
Meier plot for other variables (Gregory, 1988).
When a model contains several prognostic variables it is
sometimes useful to construct a prognostic index, which is a
new variable combining the information from all the prog-
nostic factors. For example, Palmer et al. (1980) developed a
multivariate Cox model in which the relative risk for relapse
in children with acute lymphoblastic leukaemia who achieve
a first complete remission was expressed as a linear function
0.875 z, + 0.709 Z2 -0.389 Z3, where z, denotes logarithm of
initial white blood count, Z2 is a code for FAB morphological
classification (0 for LI, 1 for L2 or L3) and Z3 is the
logarithm of 1 plus the proportion of lymphoblasts with
periodic acid-Schiff (PAS)-positive coarse granules on
blocks. From this relationship, the authors defined four risk
groups based on ranges of the total risk score. An alternative
approach to establishing risk groups is the use of recursive
partitioning or classification trees (Schmoor et al., 1993).
This involves, however, the selection of a model from a very
large number of possible interaction models. This approach
also typically includes the optimisation of marker cut-off
values. Hence, it is very important that models developed in
this way be confirmed on independent data before accep-
tance.
Determining which patients benefit from treatment
Many cancer treatments are expensive or toxic, and treating
the many for the benefit of the few is undesirable. Physicians
are often interested in trying to determine which patients are
likely to benefit from a treatment so that therapy can be
individualised. For example, investigators may take patients
from a randomised clinical trial comparing no systemic treat-
ment or a standard regimen with a new regimen to determine
whether factors identify subsets of patients who do or do not
benefit from the new treatment.
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Frequently investigators assume that if they find a statis-
tically significant treatment difference in one subset of
patients but not in another then they have identified treat-
ment specificity. For example, Gusterson et al. (1992) report-
ed that adjuvant chemotherapy was more effective in breast
cancer patients with c-erbp-2 overexpression than in patients
without overexpression. Usually, however, the statistical
power for detecting treatment differences within patient
subsets is generally quite low, especially when the subset has
a better than average prognosis. Hence, the lack of statistical
significance in a subset does not establish treatment equiva-
lence in that subset nor does significance in one subset only
necessarily indicate a differential effect. Confidence intervals
for the treatment differences are more useful than statistical
significance interpreting treatment specificity (Simon, 1986;
Gardner & Altman, 1989).
In addition to computing confidence intervals for treat-
ment effects within subsets, investigators should test for
significance of the interaction between treatment effects and
patient subsets. Such interaction tests, as described by Simon
(1982), directly test the hypothesis of homogeneity of treat-
ment effects and are more appropriate than tests of treatment
effects within individual subsets. Although an interaction test
may itself have limited power for detecting subset-specific
differences, investigators should be obliged to demonstrate
significant interactions before focusing on treatment effects
within subsets. This is because the probability of finding
some subset in which the true treatment difference is not
significant and another in which it is significant is very high
by chance alone even if the treatment difference is completely
uniform across subsets (Buyse, 1989). Also, since we do not
expect important interactions a priori, it is appropriate to
require strong evidence before accepting such claims.
The more subsets one examines, the more likely it is that
spurious subset effects will appear. Hence, it is usually best to
limit subsets examined to those specified by factors used for
stratification in the trial or for which biologically meaningful
subset hypotheses have been stated before examining the
data. This is particularly important because the interaction
test used should test the global null hypothesis that there are
no treatment-by-subset interactions for any subsets examin-
ed. For example, in analysing whether the effect of adjuvant
chemotherapy varied among patients with rectal cancer,
Fisher et al. (1988) restricted the analysis to the subsets
determined by the three factors used to stratify the ran-
domisation - age, sex and stage - and performed a global
interaction test. Dixon and Simon (1992) applied a Bayesian
subset analysis method based on stratification variables to a
randomised trial for patients with advanced colon cancer.
Peto (1982) distinguished quantitative interactions, in
which the size of the effect varies among subsets, from the
more important qualitative interactions, in which the direc-
tion of the effect varies. Gail and Simon (1985) developed a
test for qualitative interactions.
Claims of treatment selectivity can be very important;
however, most such claims are not found to be confirmable
on independent data. For example, the report that oestrogen
receptor negativity in patients with metastatic breast cancer
predicts for responsiveness to chemotherapy (Lippmann et
al., 1978) has not been widely accepted. Because of the
potential impact of such claims on both clinical research and
patient care, it may be appropriate to require additional
measures for their evaluation. Authors should indicate what
subset analyses were performed and whether any represented
prespecified hypotheses. Authors should specifically seek out
confirmatory or refutatory evidence from similar clinical
trials even if that involves contacting other trial organisers
and requesting that they examine those subsets. Since subset
analyses are often problematical, authors could also be
encouraged to provide their data on request to other inves-
tigators for independent analysis.
Randomised clinical trials can provide clear answers to
focused prestated hypotheses about treatment effectiveness
when a large enough sample size is available. When the
hypotheses are generated by the data or by performing
numerous exploratory analyses, then the results should be
viewed as hypotheses to be tested on independent data.
When there are a small number ofprestated hypotheses, then
the methods mentioned above, together with other approaches,
are useful for controlling the problem of multiple tests and
reaching conclusions in which confidence may be placed.
Since clinical trials are rarely large enough to allow reliable
evaluation of whether treatment effects vary among subsets
of patients, the findings of such analyses will often be incon-
clusive and will require data from other similar trials for
more adequate assessment.
Meta-analysis of prognostic factor studies
For some markers there have been several published studies,
often with conflicting results (e.g. O'Reilly & Richards, 1992).
The question then arises as to whether it is possible to
combine the information in the various studies. Such a 'meta-
analysis' is far more problematic than combining the results
of clinical trials. First, in reports of studies in which a factor
was not found to be statistically significant, often no quanti-
tative information is given beyond a P-value or even just
'NS'. Second, there may be more extreme publication bias, in
that researchers may not write up their results if they had a
'negative' finding, and editors may be less interested in pub-
lishing them. Third, even when numerical results are avail-
able, they will relate to a mixture of different categorisations
(some based on the biased 'optimal' cut-off point approach)
and possibly also some results with the factor treated as
continuous. Fourth, the inclusion criteria may differ marked-
ly. Fifth, the assays used and the way they are performed will
often differ among studies. Further, while it would be
desirable to take account of other prognostic variables, this
will have been done differently in the various studies. As an
example, Altman et al. (1994) reported a large number of
different cut-off points used in studies to investigate the
prognostic importance of S-phase fraction (SPF) in breast
cancer. It was noteworthy, however, that all studies found an
effect in the same direction, i.e. that high SPF is bad. These
difficulties are far greater than those encountered when trying
to overview randomised clinical trial results, so that it is
effectively impossible to perform a meta-analysis using the
information in published papers.
There seem to be two realistic options to clarify a confused
literature regarding a particular prognostic factor. First, one
could attempt to acquire the individual patient data from
many (preferably all) published studies, as is done in some
meta-analyses of clinical trials. However, it might prove
difficult to acquire the data. Also, this approach could not
overcome publication bias and would not address differences
in assay methods. However, there are recent encouraging
examples of cooperative studies (Rawson & Peto, 1990).
Alternatively, one could start afresh with a large, well-
designed prospective or retrospective phase III study (Shipp
et al., 1993).
Reporting prognostic factor studies
The authors of publications on prognostic factors should
describe the entire study. This should include how the
patients (or samples) were selected and what cases were
omitted from the analyses (i.e. inclusion and exclusion
criteria). The relevant clinical and demographic characteris-
tics of the sample should be described, and it may be useful
to tabulate these against the prognostic factors of special
interest.
Authors should describe all analyses performed, not just
those analyses and variables selected for inclusion in the
report. If specific fully stated hypotheses and specific objec-
tives were developed before the analyses began, that should
be indicated; otherwise the absence of such planning should
be noted. This is an important component of determining984 R. SIMON & D.G. ALTMAN
whether the study should be considered an exploratory
(phase II) or confirmatory (phase III) investigation.
Other aspects of reporting phase III studies are indicated
in Table I. More general suggestions regarding the presenta-
tion of the study results and of survival analyses in particular
are considered in later editorials in this series (Altman &
Machin, 1994; Bliss et al., 1994).
Conclusions
Prognostic factor evaluations are important but complex.
Currently, they are often unreliable. Greater attention is
needed in the planning and analysis of such studies. Major
prognostic factor studies should generally be planned and
conducted as confirmatory studies with specified hypotheses
and attention to limiting and controlling problems of multi-
plicity. When they are not conducted in that way, the studies
should be clearly labelled as phase I or phase II investiga-
tions that require phase III confirmation before the results
are used for medical decision making or planning of clinical
trials. Adequacy of sample size should be critically assessed
and confidence intervals used in reporting results. Interaction
tests should be used for supporting claims that the effect of
treatment or a marker varies among subsets and the use of
stepwise regression and cut-off points should be handled with
statistical care and preferably avoided. Reliable conclusions
about a factor are more likely to arise from large, possibly
collaborative, confirmatory (phase III) studies than from a
plethora of undersized studies using a variety of statistical
methodology and clinical inclusion criteria. A set of guide-
lines for the conduct and reporting of phase III prognostic
factor studies is proposed in Table I.
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